Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry.
Details
Serval ID
serval:BIB_FACFF5457A1C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry.
Journal
Thrombosis research
Working group(s)
RIETE Investigations
Contributor(s)
Arcelus J.I., Ballaz A., Barba R., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Casado I., Culla A., de Miguel J., del Toro J., Díaz-Peromingo J.A., Falgá C., Fernández-Capitán C., Font C., Font L., Gallego P., García-Bragado F., Gómez V., González J., Grau E., Grimón A., Guil M., Guirado L., Gutiérrez J., Hernández G., Hernández-Blasco L., Jara-Palomares L., Jaras M.J., Jiménez D., Lacruz B., Lecumberri R., Lobo J.L., López-Jiménez L., López-Reyes R., López-Sáez J.B., Lorente M.A., Lorenzo A., Madridano O., Marchena P.J., Martín-Antorán J.M., Martín-Martos F., Monreal M., Morales M.V., Nauffal D., Nieto J.A., Núñez M.J., Odriozola M., Otalora S., Otero R., Pagán B., Pedrajas J.M., Pérez C., Peris M.L., Porras J.A., Portillo J., Reig O., Rivas A., Rodríguez D.A., Rodríguez-Dávila M.A., Rosa V., Ruiz-Artacho P., Ruiz-Giménez N., Ruiz-Martínez C., Sampériz A., Sala C., Sancho T., Sanz O., Soler S., Suriñach J.M., Tiberio G., Tolosa C., Trujillo-Santos J., Uresandi F., Valle R., Vela J., Vidal G., Villalta J., Malfante P.C., Vanassche T., Verhamme P., Wells P., Hirmerova J., Malý R., Raupach J., Salgado E., Bertoletti L., Bura-Riviere A., Farge-Bancel D., Hij A., Mahé I., Merah A., Quere I., Papadakis M., Braester A., Brenner B., Tzoran I., Apollonio A., Barillari G., Bertone A., Bilora F., Candeloro G., Ciammaichella M., Di Micco P., Ferrazzi P., Grandone E., Lessiani G., Lodigiani C., Mastroiacovo D., Pace F., Pesavento R., Pinelli M., Prandoni P., Rosa M., Rota L., Tonello D., Tufano A., Visonà A., Zalunardo B., Belovs A., Skride A., Ribeiro J.L., Seabra F., Sousa M.S., Bosevski M., Zdraveska M., Alatri A., Bounameaux H., Calanca L., Mazzolai L.
ISSN
1879-2472 (Electronic)
ISSN-L
0049-3848
Publication state
Published
Issued date
12/2015
Peer-reviewed
Oui
Volume
136
Number
6
Pages
1199-1203
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
There is uncertainty about the optimal therapy of venous thromboembolism (VTE) in patients with glioblastoma multiforme (GBM).
We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in patients with GBM, other cancers and in patients without cancer.
As of September 2014, 53,546 patients have been recruited in RIETE. Of these, 72 (0.13%) had GBM and 11,811 (22%) had other cancers. Most patients in all 3 subgroups received initial therapy with low-molecular-weight heparin (LMWH), but those with GBM received slightly lower doses than those with other cancers or without cancer. Then, most patients with GBM continued on LMWH for long-term therapy, at similar doses than those in the other subgroups. During the course of anticoagulation (mean, 202 days), 3 patients with GBM presented VTE recurrences (10.9 per 100 patient-years; 95% CI: 2.76-29.5) and 4 suffered major bleeding (one intracranial) (14.5 bleeds per 100 patient-years; 95%CI: 4.60-34.9). Compared with patients with other cancers, those with GBM had a similar rate of VTE recurrences and major bleeds, but had a higher rate of extracranial hematoma (p<0.05). Compared with VTE patients without cancer, those with GBM had a higher rate of PE recurrences (p<0.01) and major bleeding (p<0.001), particularly extracranial hematoma (p<0.001).
Patients with GBM and VTE had a similar rate of VTE recurrences or major bleeds during the course of anticoagulant therapy than those with other cancers.
We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in patients with GBM, other cancers and in patients without cancer.
As of September 2014, 53,546 patients have been recruited in RIETE. Of these, 72 (0.13%) had GBM and 11,811 (22%) had other cancers. Most patients in all 3 subgroups received initial therapy with low-molecular-weight heparin (LMWH), but those with GBM received slightly lower doses than those with other cancers or without cancer. Then, most patients with GBM continued on LMWH for long-term therapy, at similar doses than those in the other subgroups. During the course of anticoagulation (mean, 202 days), 3 patients with GBM presented VTE recurrences (10.9 per 100 patient-years; 95% CI: 2.76-29.5) and 4 suffered major bleeding (one intracranial) (14.5 bleeds per 100 patient-years; 95%CI: 4.60-34.9). Compared with patients with other cancers, those with GBM had a similar rate of VTE recurrences and major bleeds, but had a higher rate of extracranial hematoma (p<0.05). Compared with VTE patients without cancer, those with GBM had a higher rate of PE recurrences (p<0.01) and major bleeding (p<0.001), particularly extracranial hematoma (p<0.001).
Patients with GBM and VTE had a similar rate of VTE recurrences or major bleeds during the course of anticoagulant therapy than those with other cancers.
Keywords
Aged, Anticoagulants/therapeutic use, Brain Neoplasms/complications, Brain Neoplasms/diagnosis, Data Collection, Databases, Factual, Europe, Female, Glioblastoma/complications, Hematoma/complications, Hemorrhage, Heparin, Low-Molecular-Weight/therapeutic use, Humans, International Cooperation, Male, Middle Aged, Recurrence, Registries, Treatment Outcome, Venous Thromboembolism/complications, Venous Thromboembolism/prevention & control, Anticoagulant therapy, Bleeding, Glioblastoma, Recurrences, Venous thromboembolism
Pubmed
Web of science
Create date
08/05/2020 13:38
Last modification date
02/06/2020 14:31
Usage data
